Kineta Announces First Patient Dosed In Phase 1/2 VISTA-101 Clinical Trial Of KVA12123 In Combination With KEYTRUDA In Patients With Advanced Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Kineta, Inc. (NASDAQ:KA) has announced the first patient dosing in Part B of its Phase 1/2 VISTA-101 clinical trial. The trial will evaluate the safety and tolerability of Kineta's VISTA blocking immunotherapy, KVA12123, in combination with Merck's anti-PD-1 therapy KEYTRUDA in patients with advanced solid tumors. Initial combination therapy clinical data is expected in Q2 2024.
October 17, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Kineta's initiation of patient dosing in its Phase 1/2 trial of KVA12123 with KEYTRUDA could potentially advance the company's oncology portfolio. However, the results and potential impact on the company's stock will not be known until Q2 2024.
The initiation of patient dosing in Kineta's Phase 1/2 trial is a significant step in the development of its oncology portfolio. However, the impact on the company's stock will depend on the results of the trial, which are not expected until Q2 2024. Therefore, the short-term impact on the stock is neutral.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100